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Summary.-Local tumour control has been determined at 150 days after single doses
of 240 kV x-rays given with or without 1 mg/g body weight of the hypoxic cell radio-
sensitizer Ro-07-0582. The dose required to control 500/ of the tumours (TCD50)
was reduced from 4380 to 2410 rad, yielding an enhancement ratio of 1-82 i 0-07
s.e.mean. This compares favourably with the corresponding single dose gain factor
for fast neutrons, which was about 1 -7.
THE PRESENCE ofhypoxic andtherefore
radioresistant cells in tumours has been
suggested as a possible cause of failure
to eradicate some tumours using radio-
therapy (Fowler, 1972, gives a recent
review). The most likely explanation
for the existence of hypoxic tumour cells
is that oxygen is rapidly used up by
metabolism in cells through which it
diffuses when it passes out ofaninadequate
capillary network, so that no oxygen is
available to reach cells situated more
than about 200 jim from capillaries
(Thomlinson and Gray, 1955). Com-
pounds are being investigated which
mimic the electron affinic property of
oxygen, and might therefore be radio-
sensitizers, but which are capable of
diffusing further from capillary vessels
because they are not rapidly metabolized
in the cells (Adams, 1973).
Two promising compounds are at
present under investigation. First, the
5-nitroimidazole, metronidazole (Flagyl,
May & Baker Ltd, Dagenham, Essex
(mol. wt - 171)), which gives sensitizing
enhancement ratios (ER) of 158 in vitro
(Asquith et al., 1974a, b; Chapman,
Reuvers and Borsa, 1973) and 1.4 for
cells made hypoxic in vivo (Denekamp,
Michael and Harris, 1974). Second, the
2-nitroimidazole, Ro-07-0582 (Roche Pro-
ducts Ltd, Welwyn Garden City, Herts
(mol. wt 200.1)), which gives higher
ERs of 2*5 in vitro (compared with the
full oxygen ER of 2.8) and of about 2 in
mouse skin made artificially hypoxic in
vivo (Denekamp et al., 1974). In all the
experiments just quoted, the concentra-
tion of drug in the medium (in vitro)
and in serum (in vivo) at the time of
irradiation was 5 mmol/l (850-1000 pg/ml)
for both of the nitroimidazoles.
These enhancement ratios are suffi-
ciently large for applications to radio-
therapy in man to be seriously considered.
The present experiments on local control
of solid tumours in mice were therefore
undertaken.
In solid experimental tumours in C3H
mice breathing warm oxygen, local control
was enhanced by metronidazole in the
x-ray dose ratio of 1*4 (Begg, Sheldon
and Foster, 1974). The present paper
reports the results of experiments on
local control of similar tumours using
Ro-07-0582.
MATERIALS AND METHODS
C3H/He mice bred atthe GrayLaboratory
were used at age 12 weeks. Spontaneous
mammary tumours from syngeneic mice wereRADIOSENSITIZATION OF HYPOXIC CELLS IN TUMOURS
cut into approximately 1 mm cubes and
implanted subcutaneously on the ventral
surface of the thorax. Batches of 70-100
mice were transplanted from 1, 2 or 3 spon-
taneous tumours and mice were drawn
randomly from several such transplants.
The tumours grew wxith a mean doubling
time of 6 days (range 3-12 days) and were
irradiated whentheyreached a mean diameter
of 6-5 ± 1 mm.
For irradiation, the mice were anaesthe-
tized with 60 mg/kg sodium pentobarbitone
and breathed 100% oxygen at atmospheric
pressure warmed to 25 ± 1C, for consistency
with previous experiments (Hill et al., 1970;
Fowler et al., 1974). The proportion of
hypoxic cells present before irradiation under
these conditions was known from other
experiments to be about 10% (Fowler et al.,
unpublished). This proportion islarge enough
to be the determining factor in response of
the tumours to single doses of x-rays greater
than 500 rad (assuming n = 2, Do = 130 rad
and OER = 2-5 or 3)* or 700 rad (assuming
n = 20 and Do and OER as before). The
measured enhancementratios, however, would
be appreciably smaller for test doses of 1000
rad than for 2000 rad or higher doses. Mice
were randomized into control or drug treated
groups. Mice treated with the drug were
given 1 mg/g body weight of Ro-07-0582
dissolved in warm, normal saline by intra-
peritoneal injection 30 min before irradiation
started. Single doses of x-rays were given,
the mice being turned through 180° halfway
through the irradiation.
Irradiations were carried out as described
previously (Fowler et al., 1974), using 240 kV
x-rays with h.v.l. 1-3 mm Cu and dose
rate 240 rad/min. The mice were irradiated
prone in a lead cradle with a hole 2-5 x 2-0
cm, through which the tumour hung freely
during tangential irradiation with a hori-
zontal beam. The dose rate at the centre of
the thorax due to scattered radiation was
measured as 22 rad per krad delivered to the
tumour. After irradiation, the mice were
revived with 0-5 mg per mouse of bemegride.
The mice were kept for 150 days or until the
treated tumours regrew to more than 6 mm
mean diameter when they were scored as
" recurred ". Mice were scored as " cured "
if the tumours were less than 4 mm in mean
diameter at 150 days after irradiation. There
were no tumours between 4 and 6 mm in
diameter at 150 days, which would have been
scored as " ambiguous " and rejected from
the analysis. The results were analysed
using a computer programme developed by
Dr E. H. Porter of the Glasgow Institute of
Radiotherapeutics and Dr L. J. Peters of the
Gray Laboratory. The programme assumes
single-cell kinetics so that the tumour control
probability is given by exp (-SN) where N
is the initial number of clonogenic cells in the
tumour and S is a surviving fraction. S is
assumed to be an exponentially decreasing
function of x-ray dose.
RESULTS
The results are shown in Table I and
the Fig. In Table II the fate of the
experimental mice is shown: Ro-07-0582
appears slightly toxic at this high concen-
tration, in contrast to metronidazole
when used in conjunction with x-rays,
with which no deaths that could be attri-
buted to gut injury occurred (Begg et al.,
1974). Eighty mice given a single dose
of 1 mg/g of Ro-07-0582 showed no deaths
up to 100 days. Although a significant
difference had been demonstrated in
TCD50 between the sexes in previous
work (Fowler et al., 1974), only small
differences were found in the present
results. The results presented are cor-
rected to equal proportions of male and
female mice; the corrections were small
(Table I). The ratio of TCD50s is
4380/2410 1*82 ± 0*07 s.e.mean.
The slopes ofthe curvesrelatingtumour
control to x-ray dose are significantly
different (Fig.). The corresponding D0
values which provide the best fit to the
data are 900 rad for x-rays only and 500
for x-rays plus Ro-07-0582. The value
of900 rad is consistent with many previous
experiments using different radiosensi-
tizers or fractionation schedules which
were less effective (Fowler et al., 1947).
The ratio of the inverse slopes D0 is
900/500- 180 i 0-09 s.e.mean, which
* n = extrapolation number of cell survival curve; D° = inverse slope of survival curve of well oxygen-
ated cells; OER = oxygeni enhancement ratio.
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TABLE I.-Tumours Controlled at 150
Days as a Proportion ofThose Analysed.
The TCD50 Values and S.E. Means are
Given
Male Female
rad x-rays only
0/2 0/10
2/4 0/7
0/6 0/6
3/8 3/8
2/7 2/7
4/7 6/8
6/6 4/7
6/7 6/7
11/11
58 60
4195 4570
280 200
1300 800
half M & half F
X-rays + Ro-07-0582
0/6 0/4
0/6 0/7
2/5 0/5
7/9 1/6
2/6 4/7
6/6 7/7
4/5 4/4
6/6 4/4
49 44
2320 2505
140 75
610 200
half M & half F
-J
0
z
0
n I-)
cr
0
2 D
ll
0
z
0
H 0.
0 a a-
Both
0/12
2/11
0/12
6/16
4/14
10/15
10/13
12/14
11/11
118
4410
155
900
4380
0/10
0/13
2/10
8/15
6/13
13/13
8/9
10/10
93
2400
85
500
2410
TABLE II.-Fate of the Experimental Mice
(Percentage in Brackets)
Mice
Total irradiated
Failed to recover
from anaes-
thetic at
irradiation
Died early
from? trauma
of oral
administration
Died early from
gut injury seen
at p.m.
Died from other
causes (lung
metastases,
spontaneous
tumours
elsewhere)
Available for
analysis
Females
Males
Mice with lung
metastases
found at p.m.:
With tumours
controlled
With tumours
recurred
X-rays
only
139 (100)
Metro-
ni(dazole
+x-rays
92 (100)
Ro-07-0582
+x-rays
154 (100)
1 (0 7) 1 (1 1) 18 (11.7)
NA 5 (5.4) NA
9 (6 5) 0 (0)
11 (7 9)
118 (85)
60
58
5/54
2/44
12 (11)
74 (68)
22
52
2/47*
5/21**
* Conltemporanieous x-rays only 1/20.
** Cointemporaneous x-rays only 4/14.
23 (14.9)
20 (13-0)
93 (61)
44
49
4/57
6/41
X- RAY DOSE (k rad)
FIG. Proportion of tumours controlled at 150 days vs x-ray dose. Right hand curve, x-rays only.
Left hand curve, x-rays delivered starting 30 min after i.p. injection of 1 mg/g bodyweight of
Ro-07-0582.
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2600
3000
3400
3800
4400
4800
5200
5600
6200
mice:
TCD50
S.e.means
Do
TCD50
1500
1700
2000
2300
2600
3000
3500
4000
mice:
TCD50
S.e.means
Do
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is the same as the ratio of TCD50s. This
similarity provides clear evidence that the
Ro-07-0582 actuallyreaches all thehypoxic
cells and sensitizes them by the factor
1.8, and clear evidence against the alter-
nativepossibility that thedrugreachesonly
some ofthe hypoxic cells. The correspond-
ing slope ratio for the results on metro-
nidazole previously published (Begg et al.,
1974) was, however, consistent with either
theory.
An analysis was also done of delay in
time to regrow to 8 mm. Because about
half of the tumours were controlled, i.e.
delay for them was infinite, the average
of the reciprocal regrowth times for each
dose group was plotted against x-ray
dose. The enhancement ratio obtained
graphically varied from 1.8 to 2, in good
agreement with the ratio obtained from
the TCD50 values.
The incidence of metastases did not
appear to be influenced by Ro-07-0582.
In mice whose tumours had been con-
trolled for 150 days, 4 of 57 mice receiving
both Ro-07-0582 and x-rays developed
visible metastases, compared with 5 of
54 mice receiving x-rays only. The
incidence of metastases in mice with
locally recurrent tumours was 6/41 and
2144 respectively (not significant dif-
ference, x2 -1.4). The incidence ofmeta-
stases was not influenced by metronidazole
either in the previously described experi-
ment (Begg et al., 1974). Where tumours
had been controlled for 150 days, 2/47
mice receiving x-rays and metronidazole
developed metastases (compared with
1/20 in contemporaneous controls). The
incidence for mice with locally recurrent
tumours was 5/21 (cf. 4/14 in controls).
These results are important in view of the
finding that the drugs alone, without
x-irradiation, caused a small delay in
regrowth or reduction in size of the solid
tumours (Begg et al., 1974; Denekamp and
Harris, unpublished). This delay or re-
gression cannot be attributed to a drug
stimulated loss of viable cells from the
tumour volume.
When Ro-07-0582 was given 20 min
after finishing the x-ray exposure, the
TCD50 for 50% males and females
(obtained from an experiment with 23
males and 25 females) was 4457 + 220
rad (s.e.mean), which is not significantly
different from the x-ray only group.
DISCUSSION
The enhancement ratio ER - 1-82
means that, in this tumour system, at a
dose of 3800 rad the proportion cured
rises from 3000 in control mice to nearly
100% in mice treated with 1 mg/g of
Ro-07-0582 (Fig.). This value is similar to
the ER of 1-9 found for the KHT sarcoma
irradiated in air breathing mice and
assayed in vitro (Rauth, unpublished);
slightly less than the ER of 2.1 for
regrowth delay in the murine carcinoma
NT (Denekamp and Harris, unpublished);
and of 2 1 for the CBA mouse sarcoma F
irradiated in vivo and assayed in vitro by
Dr N. J. AIcNally; and of about 2 found
by Dr L. J. Peters using local control of
intradermal squamous cell carcinomata:
but somewhat greater than the ER of
1.6 observed by Mr A. C. Begg using either
regrowth or loss of incorporated 125IUdR
after treating the CBA mouse sarcoma F
with x-ray doses of 1000-1500 rad,
(private communications). The latter en-
hancementmayhave been made low bythe
use of the relatively low x-ray test dose.
All the results quoted are for air breathing
mice given 1 mg/g of Ro-07-0582 intra-
peritoneally 20-60 min before irradiation.
These results show that a large
increase in the proportion of tumours
locally controlled can be obtained using
radiosensitizing drugs and x-rays. The
drug appears to diffuse out from capillaries
to the hypoxic cells normally present in
tumours and is effective as a sensitizer of
these hypoxic cells in vivo. The enhance-
ment ratios, like those for other sensitizers
tested in vivo (Denekamp and Michael,
1972; Hewitt and Blake, 1970; Sheldon
and Smith, 1974), are somewhat less than
would be expected from the in vitro results
with concentrations in the medium ofdrug
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equal to the peak serum concentrations in
vivo, although firmvaluesfor concentration
of the drug in the relevant hypoxic cells
are not known and would be difficult to
obtain.
These ERs were obtained using rela-
tively large quantities of drug: 1 mg/g
corresponds to 50 g to a 50 kg patient on a
weight-for-weight basis. This may cor-
respond to 20-80 g on the basis of peak
serum concentrations measured after very
low doses. No such measurements in
patients for Ro-07-0582 have yet been
made at these high doses.
The main toxicological problem in
the clinical use of metronidazole as a
radio-sensitizing drug appears to be the
acute nausea caused by several repeated
doses of 5-10 g (i.e. 50-100 mg/kg) which
persisted for 1 or 2 days after stopping
the administration of the drug (Urtasun
et al., 1974; Deutsch et al., 1974). There-
fore, it is not expected that significantly
higher doses than these can be used clinic-
ally. Ten to 30 repeated doses would be
needed for a course of radiotherapy
depending on whether 2, 3 or 5 sessions
per week were administered, with 2
sessions per week obviously preferable on
toxicological grounds.
An increase in the incidence oflympho-
sarcomata and lung tumours in mice, by
approximately a factor of 2, has been
reported for mice given daily doses of up
to about 830 mg/kg of metronidazole
throughout life (Rustia and Shubik, 1972).
No such effect was found in rats (Cohen
et al., 1973). This is probably not a
major hazard for patients who already
have a malignant tumour requiring treat-
ment.
A more serious question arises from
reports of cerebellar damage in dogs.
Repeated daily doses given to dogs of
either metronidazole (150 or 250 mg/kg)
or the 2-nitroimidazole compound Ro-07-
1051, similar in structure to Ro-07-0582,
(50, 100 or 150 mg/kg) caused bouts of
ataxia, then continuous muscle spasm
and cerebellar cell degeneration, ending in
death. If the drug was withdrawn when
the bouts began and sedatives were given,
no further harmful effects were seen.
Experiments in other species, however,
indicate that the dog is atypically sensi-
tive to this kind of cerebellar damage
(Scharer, 1972). No such neurological
symptoms were seen with similar or
larger daily doses of Ro-07-1051 in mice,
rats, guinea-pigs or rabbits. Further,
the differences in structure and solubility
of the two compounds suggest that Ro-07-
0582 should not be more toxic than Ro-07-
1051. The toxicology of Ro-07-0582 itself
obviously has to be investigated further.
CONCLUSIONS
The substantial enhancement ratio of
1.8 obtained for local control ofthe present
solid tumour, using single doses of x-rays
with 1 mg/g body weight of Ro-07-0582,
compares well with the relative enhance-
ment ratio of I 7 for hypoxic cells obtained
for fast neutrons.
The disadvantage is that the large
drug doses (1000 mg/kg) required to
obtain the high enhancement ratios which
have been measured in murine tumours
do not at present appear to be feasible
clinically. At the lower drug doses which
might be clinically usable (50-100 mg/kg)
the sensitization enhancement ratioswould
be lower; they are being measured in a
variety of experimental tumour systems
and ERs in the range 1 0-1-5 can be ex-
pected (Rauth, unpublished; Hewitt et al.,
personal communications). The effects of
the drug when used with multiple small
doses ofx-rays are being tested. Different
degrees of response in different types of
tumour might be found and if so should
be investigated further. Enhancement
ratios exceeding 1 2 are required before
an effect would be clinically detectable.
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